Inovio Biomedical Corporation and VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference

SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Alternext: INO) and VGX Pharmaceuticals announced today they will make multiple presentations concerning electroporation-delivered DNA vaccines in the fight against cancer, HIV and other infectious diseases at DNA Vaccines 2008, a conference hosted by The International Society of DNA Vaccines in Las Vegas, NV, at The Tropicana Hotel, December 9-11. Inovio and VGX, co-sponsors of the event, are advancing a powerful delivery method, electroporation, to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.